标题
Emerging therapies for small cell lung cancer
作者
关键词
-
出版物
Journal of Hematology & Oncology
Volume 12, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-05-03
DOI
10.1186/s13045-019-0736-3
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor
- (2018) Chengying Xie et al. CANCER SCIENCE
- Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
- (2018) M. Catherine Pietanza et al. JOURNAL OF CLINICAL ONCOLOGY
- Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer
- (2018) Carlos Fernandez-Teruel et al. CLINICAL PHARMACOKINETICS
- Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC).
- (2018) Daniel C. Cho et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of lurbinectedin (PM1183) in small cell lung cancer (SCLC): Results from a phase 2 study.
- (2018) Jose Manuel Trigo Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.
- (2018) Hyun Cheol Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study.
- (2018) David Paul Carbone et al. JOURNAL OF CLINICAL ONCOLOGY
- Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
- (2018) Guoshuang Shen et al. Journal of Hematology & Oncology
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer
- (2018) Baohui Han et al. JAMA Oncology
- Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing
- (2018) Zihai Li et al. Journal of Hematology & Oncology
- Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
- (2017) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- The next generation of immunotherapy: keeping lung cancer in check
- (2017) Ashwin Somasundaram et al. Journal of Hematology & Oncology
- Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
- (2017) Si-Yang Liu et al. Journal of Hematology & Oncology
- Clinical applications of PD-L1 bioassays for cancer immunotherapy
- (2017) Delong Liu et al. Journal of Hematology & Oncology
- Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
- (2017) Bingshan Liu et al. Journal of Hematology & Oncology
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current Treatments for Surgically Resectable, Limited‐Stage, and Extensive‐Stage Small Cell Lung Cancer
- (2017) Thomas E. Stinchcombe ONCOLOGIST
- Treatment advances in small cell lung cancer (SCLC)
- (2017) Saiama N. Waqar et al. PHARMACOLOGY & THERAPEUTICS
- Surgery for Early-Stage Small Cell Lung Cancer
- (2017) Bryan J. Schneider et al. Journal of the National Comprehensive Cancer Network
- Small Cell Lung Cancer
- (2017) Gregory P. Kalemkerian et al. Journal of the National Comprehensive Cancer Network
- Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
- (2016) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC
- (2016) Scott J. Antonia et al. Journal of Thoracic Oncology
- ORAL02.01: Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC
- (2016) Todd M. Bauer et al. Journal of Thoracic Oncology
- Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC
- (2016) Edurne Arriola et al. Journal of Thoracic Oncology
- Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial
- (2016) Koichi Goto et al. LANCET ONCOLOGY
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
- (2016) Joohee Sul et al. ONCOLOGIST
- Small cell lung cancer, an epithelial to mesenchymal transition (EMT)-like cancer: significance of inactive Notch signaling and expression of achaete-scute complex homologue 1
- (2016) Takaaki Ito et al. Human Cell
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
- (2015) Laura R. Saunders et al. Science Translational Medicine
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer
- (2014) Taofeek K. Owonikoko et al. Cancer Medicine
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†
- (2012) M. Reck et al. ANNALS OF ONCOLOGY
- Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker
- (2012) M. C. Pietanza et al. CLINICAL CANCER RESEARCH
- Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data
- (2012) Antonio Rossi et al. JOURNAL OF CLINICAL ONCOLOGY
- Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
- (2012) Lauren Averett Byers et al. Cancer Discovery
- Treatment of extensive-stage small cell lung carcinoma: current status and future prospects
- (2010) I. K. Demedts et al. EUROPEAN RESPIRATORY JOURNAL
- Notch inhibition by the ligand Delta-Like 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis
- (2010) Gavin Chapman et al. HUMAN MOLECULAR GENETICS
- Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers
- (2010) David B Page et al. Immunotherapy
- Limited-Stage Small Cell Lung Cancer: Current Chemoradiotherapy Treatment Paradigms
- (2010) T. E. Stinchcombe et al. ONCOLOGIST
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy
- (2010) Axel Hoos et al. SEMINARS IN ONCOLOGY
- Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
- (2009) S. M. Ansell et al. CLINICAL CANCER RESEARCH
- Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124
- (2009) Primo N. Lara et al. JOURNAL OF CLINICAL ONCOLOGY
- A small-cell lung cancer genome with complex signatures of tobacco exposure
- (2009) Erin D. Pleasance et al. NATURE
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
- (2008) F. S. Hodi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started